Biotechnology company focused on developing cell therapies for solid tumors.
Lyell Immunopharma, Inc. is a pioneering T cell reprogramming company specializing in the development of innovative therapies for patients combating solid tumors. Central to its approach are cutting-edge technology platforms such as Gen-R, designed for ex vivo genetic reprogramming to overcome T cell exhaustion, and Epi-R, which facilitates the generation of T cell populations endowed with durable stemness.
The company's robust pipeline includes several promising candidates. Among these is LYL797, a T cell therapy targeting non-small cell lung cancer and triple negative breast cancers, aimed at harnessing the immune system to combat these challenging malignancies. Additionally, LYL845 represents another significant advancement, targeting multiple solid tumors with the potential to broaden treatment options across various cancer types.
In strategic collaboration with GlaxoSmithKline, Lyell Immunopharma has further strengthened its research and development capabilities. This partnership focuses on advancing the NY-ESO-1 program, which holds promise for treating synovial sarcoma and other solid tumor indications, underscoring the company's commitment to expanding therapeutic options for patients in need.
Founded in 2018 and headquartered in South San Francisco, California, Lyell Immunopharma continues to lead the charge in transforming cancer treatment paradigms through innovative immunotherapies. With a dedication to pioneering science and a collaborative approach to research and development, the company is poised to make significant strides in improving outcomes for cancer patients worldwide.